Exact Sciences Appoints Industry Analyst To New BD Role
This article was originally published in Clinica
Executive Summary
Exact Sciences Corp., maker of the Cologuard, a colorectal cancer screening test, appointed Jeff Elliott VP, business development and strategy, effective June 20. In the new role, Elliott will oversee the identification and pursuit of strategic business opportunities to help drive Cologuard's success. Elliott previously served as a senior research analyst at Robert W. Baird & Co., monitoring diagnostics and life science tools companies. Previously, he worked in a supply chain role for Walgreen Co.and as a consultant at Cap Gemini Ernst & Young. Elliott will report directly to Kevin Conroy, chairman and CEO of Exact Sciences.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.